BioInno logo — Empowering global biopharma with world-class cell culture an...

BioInno

Empowering global biopharma with world-class cell culture and GMP production services.

Founded 2019 Series A Biopharma, Biotechnology +1

General Information

Company Name BioInno
Founded Year 2019
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with BioInno. To contact BioInno, visit bioinnobio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BioInno compare?

A PDF of BioInno and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BioInno soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BioInno

BioInno is a China-based startup that aims to empower global biopharma with world-class cell culture and GMP production services. Established in 2019, BioInno offers comprehensive biopharmaceutical CDMO services and cell culture media, specializing in process development and GMP production. The company is focused on supporting businesses in bringing protein, cell therapy, and gene therapy drugs to both Chinese and global markets. In its latest milestone, BioInno secured a Series A investment on 21st December 2021. The investment was led by a consortium of investors including EFung Capital, 深圳市道合科技投资管理有限公司, Yuanqi Capital, Guoxin Investment, Yifeng Capital, Tigermed, and TaiKun Fund. With its expertise in the Biopharma, Biotechnology, and Pharmaceutical industries, BioInno stands poised to make a significant impact in the global biopharmaceutical landscape.

Business keywords: Biopharma, CDMO services, Cell culture, GMP production, Process development, Protein drugs, Cell therapy, Gene therapy, China-based, Global market, Biopharmaceutical supplier, Cell culture media, GMP, Pharmaceutical production, Drug development

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Undisclosed 7
EFung Capital, 深圳市道合科技投资管理有限公司 +5
21 Dec 2021

BioInno Alternatives & Competitors

BioInno vs

A comprehensive R&D and production platform offering complete solutions for cell and gene therapy, v...

Series C
1001-5000 employees
Biopharma, Pharmaceutical
BioInno vs

Empowering breakthroughs in Cell and Gene Therapy with comprehensive development and manufacturing s...

Series B
201-500 employees
Biopharma, Biotechnology
BioInno vs

An integrated cell and gene therapy Contract Testing, Development and Manufacturing Organization (CT...

412 employees
Biotechnology, Life Sciences

FAQ About BioInno

Empowering global biopharma with world-class cell culture and GMP production services.
BioInno was founded in 2019.
BioInno operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on Biopharma, CDMO services, Cell culture and GMP production.
BioInno has completed 1 funding round. The latest funding stage is Series A.
Top alternatives and competitors to BioInno include GenScript ProBio, Proton Bio, WuXi Advanced Therapies, BioDlink(TOT BIOPHARM), T&L Biotechnology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioInno and GenScript ProBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BioInno, https://bouncewatch.com/company/bioinno, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes